Jop Flameling

Master student of Clinical Psychology at Leiden University, interested in research methods and the scientific study of psychedelics

[Jop Flameling @FlamelingJop]

A couple of weeks ago, a Letter to the Editor concerning this paper I co-wrote was published, to which the original authors responded https://t.co/gTFx43IF1s

[Jop Flameling @FlamelingJop]

@psybalazs Interesting! Any thoughts on the difference between placebo response in ketamine trials vs these psilocybin trials? You'd think ketamine trials would suffer from similar unblinding and know-cebo issues

[Jop Flameling @FlamelingJop]

@psybalazs Or, possibility number 3: those thinking they got MDMA while they received placebo might differ on important characteristics (e.g., suggestibility), which makes them more likely to respond to the therapy component of the trial compared to the sample as a whole.

[Jop Flameling @FlamelingJop]

@psybalazs Absolutely love this @psybalazs! Especially the expectancy-adjusted treatment difference; very nice way to disentangle all the data. Love it!

[Jop Flameling @FlamelingJop]

@MichaelHaichin @JacobSAday @MichielElk Yeah, I guess so! Makes it even worse 😅

[Jop Flameling @FlamelingJop]

Preprint - Expectancy effects in MAPP2

@JacobSAday @MichielElk and I wrote a Matters Arising (Letter to the Editor) regarding the most recent phase 3 trial of MDMA-assisted therapy for PTSD.

A short summary.

https://t.co/0O2inCTbk6

[Jop Flameling @FlamelingJop]

@ee_schenberg ... because it could trigger placebo effects.

@psybalazs measured this beautifully in their self-blinding microdose study. https://t.co/4NvdwMwULQ

In the case of MAPP2, we don't know the cause of unblinding, because it wasn't measured.

[Jop Flameling @FlamelingJop]

@ee_schenberg Hi Eduardo, great point!

The difference lies in the source of unblinding. If it's benign (you know you got the treatment because you feel better), it's no problem!

If it's malicious (you know you got the treatment because you felt side-effects), it could be problematic ...

[Jop Flameling @FlamelingJop]

Tagging people I think might be interested!! @psybalazs @MattBurkeMD @EikoFried @vincepsy @NL_Mason @KettnerHannes @HengartnerMP @MichaelHaichin @ManojDoss @emma_kopra @ehaijen @m_wall @sdpnayak @D_E_McCulloch

[Jop Flameling @FlamelingJop]

With this Letter, we're trying to keep the pressure on, and raise the methodological bar for the field of psychedelics. Measure more and measure better!

Make use of the most recent methodological tools developed by the field!

[Jop Flameling @FlamelingJop]

@EconTalker Anja Shortland on Kidnap
Tamar Haspel on First-Hand Food
David Epstein on Range

[Jop Flameling @FlamelingJop]

@c_talea Might be interesting to talk to @NL_Mason? Saw they're doing a study on the same topic, giving LSD to couples iirc!